Archit Kalra
Chief Executive Officer Kalevala Therapeutics, Inc.
When he was 12, Archit Kalra watched his grandfather lose half his body mass in a month. His grandfather was later diagnosed with a kidney mutation that only five people in the world have, and even fewer know how to treat. Archit has since made it his mission to find an accessible treatment for every rare disease patient, starting with off-patent drugs that are unavailable in the US or other countries. His company Kalevala Therapeutics has achieved FDA Orphan Drug Designation for a lead candidate in neuronopathic Gaucher Disease and has multiple candidates heading toward the clinic.
Seminars
Tuesday 20th October 2026
Defining the Role of Expanded Access in Rare Diseases from Concept to Readiness
5:15 pm
- Exploring where expanded access delivers the greatest value within rare disease development and patient access strategies
- Preparing operationally and regulatorily for expanded access programmes prior to launch
- Aligning expanded access with broader regulatory pathways and evidentiary expectations
- Understanding the role of expanded access beyond data generation focusing on patient need and access equity
